Embassy Developments Shares Under Enhanced Surveillance After 25% Price Rise; Reports Record Q4 Pre-sales
Embassy Developments' shares have been placed under enhanced surveillance (IBC Stage 1) following a price increase exceeding 25% over five trading sessions. Despite regulatory action, the company reported record quarterly performance with Q4 FY26 pre-sales of ₹2,632 crore and annual pre-sales of ₹4,631 crore. The NCLAT hearing regarding CIRP proceedings has been adjourned to April 17, 2026.

*this image is generated using AI for illustrative purposes only.
Embassy developments has informed stock exchanges that its equity shares have been moved to enhanced surveillance measures following significant price movements, while simultaneously reporting record quarterly business performance.
Surveillance Action Implementation
Effective April 10, 2026, the company's equity shares have been moved from IBC Stage 0 to IBC Stage 1 under the Additional Surveillance Measure (ASM) Framework. This action was taken by both BSE Limited and National Stock Exchange of India Limited due to an upward price variation exceeding 25% over five trading sessions.
| Parameter: | Details |
|---|---|
| Effective Date: | April 10, 2026 |
| Trading Frequency: | Once per week (first trading day) |
| Price Movement: | Over 30% in last six trading sessions |
| Surveillance Stage: | IBC Stage 1 under ASM Framework |
The company noted that the upward movement reflects strong investor and shareholder confidence in its fundamentals and outlook. Under the current framework, shares will be traded once a week as a temporary surveillance measure aimed at ensuring orderly market conduct.
Record Financial Performance
Despite the surveillance action, Embassy Developments reported exceptional business performance for Q4 FY26, achieving its highest-ever quarterly pre-sales. The company filed its Q4 and FY26 operational update with stock exchanges on April 9, 2026.
| Metric: | Q4 FY26 | Growth |
|---|---|---|
| Pre-sales: | ₹2,632 crore | +89% QoQ |
| Collections: | ₹577 crore | +39% QoQ |
| Annual Performance: | FY26 | Growth |
|---|---|---|
| Pre-sales: | ₹4,631 crore | +128% YoY |
| Collections: | ₹1,721 crore | Including ₹47 crore from land monetisation |
During Q4 FY26, the company strengthened its launch pipeline with RERA registration for Embassy Serenity, Alibaug (Phase I), and recorded strong market response to launches of Embassy Citadel, Worli and Embassy Verde 2, Bengaluru.
Legal Proceedings Update
The NCLAT hearing regarding the Corporate Insolvency Resolution Process (CIRP) matter was scheduled for April 10, 2026. However, the respondent's counsel requested an adjournment, which was granted by the Hon'ble NCLAT with an observation that no further adjournment shall be sought by the respondents. The matter has been rescheduled for April 17, 2026.
Company's Financial Position
Embassy Developments management has reiterated several key points regarding its current status:
• The stay granted by NCLAT continues to be in force • The company is not subject to CIRP under the Insolvency and Bankruptcy Code • The matter relates to an exposure of approximately ₹370 crore, which is limited when viewed against the company's net equity base • The company has no debt-obligation, with documents relating only to a contingent equity infusion obligation as a secondary obligor • Operations continue in the normal course with the company remaining financially sound
The company emphasized that it is not undergoing Corporate Insolvency Resolution Process and continues to remain financially sound and fully operational, with the impugned NCLT order remaining stayed by the NCLAT.
Historical Stock Returns for Embassy Developments
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.00% | +15.43% | -8.94% | -47.19% | -49.99% | -34.88% |
How will the weekly trading restriction under ASM Stage 1 impact Embassy Developments' liquidity and institutional investor participation?
What specific factors could lead to the company's shares being moved to higher surveillance stages or removed from ASM framework entirely?
Will the NCLAT ruling on April 17, 2026 regarding the ₹370 crore exposure significantly affect the company's expansion plans and capital allocation strategy?


































